

Immune Design Investor Relations Department Immune Design Corp. Attn: Accounts Payab 601 Gateway Blvd. Suite 250 South San Francisco, CA 94080 United States

Visit IR website ☐ Sign-up for Email alerts ☐

NASDAQ: IMDZ Last Trade: 10.35 Trade Time: 4:00 PM ET Sep 20, 2017 Change: 0.45 ♣ (+4.545%) Day Range 9.90 - 10.45 52-Week Range 4.50 - 13.05 Volume 143,165

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Immune Design is a clinical stage immunotherapy company employing nextgeneration in vivo approaches to enable the body's immune system to fight disease. The company's technologies are engineered to activate the immune system's natural ability to create tumor-specific cytotoxic T cells to fight cancer and other chronic diseases. Immune Design's clinical programs are the product of its two synergistic discovery platforms: ZVexTM and GLAASTM.

... (more)

Stock Performance



Press Releases [View all]

Sep 8, 2017

New Randomized Data From CMB305 + Checkpoint Inhibitor Study Demonstrate Greater Clinical Benefit and Immune Response

Sep 1, 2017

Immune Design to Present at Upcoming Investor Conferences in September

Aug 30, 2017

Immune Design Announces New CMB305 + Checkpoint Inhibitor Topline Data from an Upcoming Presentation at the ESMO 2017 Congress

Aug 2, 2017

Immune Design Reports Second Quarter 2017 Financial Results and Provides Corporate Update

Jul 26, 2017

Immune Design to Report Second Quarter
2017 Financial Results & Provide Corporate
Update

Upcoming Events [View all]

Sep 28, 2017 10:30 AM ET

Leerink Partners Roundtable Series: Rare

Disease & Immuno-Oncology

Financials [View all]

Second Quarter Financial Results

Mar 7, 2017

Annual Report (10-K)

Apr 26, 2017

Proxy Statement (DEF 14A)

Aug 2, 2017

Quarterly Report (10-Q)

May 4, 2017

Quarterly Report (10-Q)

Nov 9, 2016

Quarterly Report (10-Q)